Impact of Lylalutide combined with insulin pump on metabolic indicators in patients with type 2 diabetes mellitus and metabolic syndrome

doi:10.3877/cma.j.issn.2095-9605.2020.03.009

Abstract

Abstract:

Objective

To explore the effect of liraglutide combined with insulin pump on the clinical efficacy and metabolic indexes of patients with type 2 diabetes and metabolic syndrome.

Methods

A total of 60 patients with type 2 diabetes and MetS treated in our hospital from January 2019 to February 2020 were selected and randomly divided into a combined group and a control group. The combined group was treated with liraglutide combined with insulin pump. The control group was treated with an insulin pump, and the BMI, waist circumference, blood pressure, blood glucose, glycated hemoglobin (HbA1c), and blood lipids (Total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) were compared between the two groups at the time of admission and after 2 and 12 weeks of treatment.

Results

There was no statistically significant difference in the average BMI, waist circumference and blood pressure before treatment between the two groups of patients (P>0.05). The BMI and waist circumference of the combined group after 12 weeks of treatment were significantly lower than before treatment and lower than the control group (P<0.05), the blood glucose level before treatment in both groups of patients, including fasting and 2h postprandial blood glucose levels, C peptide level and HbA1c difference was not statistically significant (P>0.05), the combination group C peptide level in treatment 2 Weeks and 12 weeks were significantly higher than the control group (P<0.05), and the HbA1c level of the combined group was significantly lower than the control group at 2 and 12 weeks of treatment (P<0.05). There was no significant difference in the average TC, TG, LDL-C, HDL-C levels between the two groups of patients before treatment (P>0.05). The levels of TC, TG and LDL-C were significantly lower than those of the control group, while the levels of HDL-C were significantly higher than that of the control group (P<0.05) .

Conclusions

In the perioperative period of weight loss and metabolic surgery, the implementation of rapid rehabilitation measures is superior to the traditional mode, which can significantly shorten the time of hospitalization, reduce postoperative complications, rapid recovery and save cost, and has outstanding application value.

Key words: Liraglutide, Insulin pump, Type 2 diabetes, Metabolic syndrome, Blood lipids

Yueguan Wu, Fan Zhao, Surong Deng. Impact of Lylalutide combined with insulin pump on metabolic indicators in patients with type 2 diabetes mellitus and metabolic syndrome[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2020, 06(03): 185-190.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2020.03.009

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2020/V06/I03/185

Figures/Tables 4

References 19

[1]	刘彦，吴波，曹雯，等．2型糖尿病患者腹臀脂肪与性别等因素的相关性研究[J/CD]．中华肥胖与代谢病电子杂志，2018，4(3)：129-135．
[2]	魏丹，孟化．BMI<35 kg/m²的肥胖症患者行代谢手术治疗的研究进展[J/CD]．中华肥胖与代谢病电子杂志，2018，4(3)：156-159．
[3]	Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus[J]. Clin Ther, 2009, 31: 2472-2488. URL
[4]	Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study[J]. Lancet, 2009, 374(9701): 1606-1616.
[5]	Rizzo M, Nikolic D, Banach M, et al. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective[J]. Clin Lipidol, 2013, 8(2): 173-181.. URL
[6]	Burgmaier M, Heinrich C, Marx N. Cardiovascular effects of glp-1 and glp-1-based therapies: implications for the cardiovascular continuum in diabetes[J]. Diabet Med, 2013, 30(3): 289-299. URL
[7]	Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human glp-1 analog, liraglutide[J]. Int J Obes (Lond), 2012, 36(6): 843-854.
[8]	中华医学会糖尿病学分会．中国2型糖尿病防治指南(2017年版)[J]．中华糖尿病杂志，2018，10(1)：4-67．
[9]	Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity[J]. Circulation, 2009, 120(16): 1640-1645.
[10]	Kostapanos MS, Katsiki N, Elisaf MS, et al. Editorial: reducing cardiovascular risk: Is low-density lipoprotein-cholesterol (ldl-c) lowering enough? [J]. Curr Vasc Pharmacol, 2012, 10(2): 173-177. URL
[11]	Sun F, Wu S, Guo S, et al. Effect of glp-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis[J]. Endocrine, 2015, 48(3): 794-803.
[12]	Yang SH, Xu RX, Cui CJ, et al. Liraglutide downregulates hepatic LDLreceptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1adependent mechanism[J]. Cardiovasc Diabetol, 2018, 17(1): 48.
[13]	Yan J, Yao B, Kuang H, et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease[J]. Hepatology (Baltimore, MD), 2019, 69(6): 2414-2426.
[14]	Li CJ, Li J, Zhang QM, et al. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in chinese subjects with poorly controlled type 2 diabetes and abdominal obesity[J]. Cardiovasc Diabetol, 2012, 11: 142.
[15]	Feher M, Vega-Hernandez G, Mocevic E, et al. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom[J]. Diabetes Ther, 2017, 8(2): 417-431.
[16]	Sposito AC, Berwanger O, Carvalho LS, et al. GLP-1RAs in type 2 diabetes:mechanisms that underlie cardiovascular effects and overview of cardiovascularoutcome data[J]. Cardiovasc Diabetol, 2018, 17(1): 157.
[17]	Tanaka A, Node K. Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials[J]. Cardiovasc Diabetol, 2019, 18(1): 19.
[18]	Chen XM, Zhang WQ, Tian Y, et al. Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes[J]. Cardiovascular diabetology, 2018, 17(1): 53.
[19]	Fan Q, Yin X, Rababa’h A, et al. Absence of Gravin Mediated Signaling Inhibits Development of High Fat Diet-Induced Hyperlipidemia and Atherosclerosis[J]. Am JPhysiol Heart Circ Physiol, 2019, 317: 793-810.

组别	N（例）	年龄（岁）	性别（男/女）	高血压（%）	冠心病（%）	吸烟（%）	病程（年）
联合组	30	52.4±4.3	18/12	22(47.9)	4(47.9)	6(14.7)	5.6±1.4
对照组	30	51.9±4.8	20/10	23(40.2)	5(40.2)	5(12.7)	5.7±1.9
t/χ2值	?	0.425	0.287	0.089	0.131	0.111	0.232
P值	?	0.672	0.592	0.766	0.718	0.739	0.817

组别	N（例）	年龄（岁）	性别（男/女）	高血压（%）	冠心病（%）	吸烟（%）	病程（年）
联合组	30	52.4±4.3	18/12	22(47.9)	4(47.9)	6(14.7)	5.6±1.4
对照组	30	51.9±4.8	20/10	23(40.2)	5(40.2)	5(12.7)	5.7±1.9
t/χ2值	?	0.425	0.287	0.089	0.131	0.111	0.232
P值	?	0.672	0.592	0.766	0.718	0.739	0.817

组别		N（例）	BMI（kg/m²）	腰围（cm）	血压(mmHg)
组别		N（例）	BMI（kg/m²）	腰围（cm）	收缩压	舒张压
联合组		30	?	?	?	?
?	治疗前	?	29.4±2.7	104.5±4.8	157±14	94±12
?	治疗后2周	?	28.6±2.9	101.6±4.5^*	155±14	92±13
?	治疗后12周	?	27.4±2.1^*#	97.3±3.9^*#	151±13	91±12
对照组		30	?	?	?	?
?	治疗前	?	29.2±2.8	105.1±4.8	159±17	96±16
?	治疗后2周	?	29.1±2.6	105.0±4.7	156±15	95±14
?	治疗后12周	?	28.8±2.5	104.8±4.5	155±14	94±15

组别		N（例）	BMI（kg/m²）	腰围（cm）	血压(mmHg)
组别		N（例）	BMI（kg/m²）	腰围（cm）	收缩压	舒张压
联合组		30	?	?	?	?
?	治疗前	?	29.4±2.7	104.5±4.8	157±14	94±12
?	治疗后2周	?	28.6±2.9	101.6±4.5^*	155±14	92±13
?	治疗后12周	?	27.4±2.1^*#	97.3±3.9^*#	151±13	91±12
对照组		30	?	?	?	?
?	治疗前	?	29.2±2.8	105.1±4.8	159±17	96±16
?	治疗后2周	?	29.1±2.6	105.0±4.7	156±15	95±14
?	治疗后12周	?	28.8±2.5	104.8±4.5	155±14	94±15

组别		N（例）	血糖（mmol/L）		C肽（ng/ml）	HbA1c（%）
组别		N（例）	空腹	餐后2 h	C肽（ng/ml）	HbA1c（%）
联合组		30	?	?	?	?
?	治疗前	?	8.6±1.8	14.7±3.2	1.7±0.5	8.7±0.9
?	治疗后2周	?	7.3±1.4^*	9.5±2.8^*	2.4±0.4^*#	7.8±0.5^*#
?	治疗后12周	?	6.9±1.3^*	8.4±1.9^*	2.9±0.5^*#	6.6±0.4^*#
对照组		30	?	?	?	?
?	治疗前	?	8.8±1.6	14.9±3.0	1.6±0.4	8.8±0.8
?	治疗后2周	?	7.5±1.5^*	9.8±2.4^*	1.7±0.5	8.2±0.6^*
?	治疗后12周	?	7.1±1.4^*	8.5±1.6^*	1.8±0.5	7.4±0.5^*

Please choose a citation manager

Content to export